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Background: We previously demonstrated a positive correlation with nursing home (NH) replacement and
donepezil (DNP) administration on lifetime expectancy after the onset of Alzheimer’s disease (AD). However, the
correlation with quality-adjusted life-year (QALY) remains to be elucidated, along with the additional impact of
concomitant cerebrovascular disease (CVD). Based upon our recently reported health state utility values, we
retrospectively analyzed the correlation with NH replacement and/or DNP administration on QALY and life
expectancy in ‘pure’ AD (without CVD) and AD with CVD patients.
Methods: All outpatients at the Tajiri Clinic from 1999–2012 with available medical records and death certificates
were included. The entry criteria were a dementia diagnosis (DSM-IV) and diagnoses of pure AD or AD with CVD
(NINCDS-ADRDA), medical treatment for more than 3 months, and follow up to less than 1 year before death. The
main outcomes were lifetime expectancy (months between the onset of dementia and death) and QALY.
Results: We identified 390 subjects, of whom 275 had the diagnosis of dementia that met the entry criteria,
including 67 pure AD, 33 AD with CVD, and 110 VaD patients. For the AD patients, 52 had taken DNP and 48 had
not received the drug due to treatment prior to the introduction of DNP in 1999 in Japan. For the pure AD group,
there were positive correlation between NH and DNP and QALY, as well as lifetime expectancy. As for the AD with
CVD group, only a correlation between DNP and lifetime expectancy was noted, with no correlation with QALY.
Conclusions: We found positive correlations between DNP administration and NH replacement and lifetime
expectancy and QALY after the onset of AD. However, concomitant CVD negated such a positive correlation with
QALY. The findings suggest that QALY in AD is affected by CVD; thus, indicating the importance of CVD prevention.
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There are no curative drugs for Alzheimer’s disease
(AD) at present; however, symptomatic drugs, such as
cholinesterase inhibitors (ChEIs) can delay progression
of the disease. This effect, combined with psychosocial
interventions, can increase the quality of life (QOL) [1].
These drugs administration can delay nursing home
placement [2] and may reduce mortality for patients
living in nursing homes [3] and in the community [4].
Beyond delayed progression and improved QOL, the
ultimate outcome of drug treatment should be measured
in terms of lifetime expectancy.
The correlations of drug therapy with lifetime expectancy
have not been fully investigated with various findings.
ChEIs were reported to be able to delay a nursing home
replacement, but have no effect on lifetime expectancy [4],
or ChEIs were associated with a lower risk of death and
myocardial infarction [5]. Using the database of all outpa-
tients with available medical records and death certificates
at the Tajiri Clinic from 1999–2012, we identified 100
patients that were diagnosed with AD; 52 had taken DNP
and 48 patients had not received the drug due to treatment
prior to the introduction of donepezil in 1999 in Japan. We
previously reported a positive impact of nursing home
(NH) placement and DNP administration on lifetime
expectancy after the onset of AD [6].
However, simple prolongation of the lifetime expectancy,
with possible decreased QOL, remains a problem. Instead,
“healthy life expectancy” has emerged as an important
issue. In this respect, the quality-adjusted life-year (QALY)
and health state utility values (HSUVs) are major QOL
scales that are used in the analyses of health economics of
diseases [7]. In Japan, the most common dementia disease
is AD with cerebrovascular disease (CVD), followed by
‘pure’AD (without CVD) [8, 9]. With respect to the need
to reconsider QALY in the context of activities of daily
living (ADL) levels in dementia, we previously calculated
the HSUVs under the conditions of AD and AD with
CVD: from previous reports and EQ-5D [10–12], we
estimated that the HSUVs of pure AD and AD with
CVD for ADL level A (independent walking and eating),
B (some problems with walking but sitting without
assistance), and C (confined to bed) [13] were 0.61 and
0.58, 0.53 and 0.28, and 0.19 and 0.05, respectively [14].
Using the same database, we re-analyzed the correlation
between NH replacement and/or DNP administration and
QALY and lifetime expectancy in AD without CVD and
AD with CVD. We hypothesized that 1) the drug would
exhibit a positive correlation with QALY as well as lifetime
expectancy in both AD without CVD and AD with CVD
patients, and 2) that NH residency would also exhibit a
positive correlation. We analyzed DNP alone, because this
drug has been used since 1999 in Japan, whereas other
drugs, such as galantamine, have only been used since2011. The combined effect of DNP and NH residency was
also analyzed. Despite the retrospective design, this was a
long-term study of the possible effect of donepezil on
QALY, as well as the life expectancy of patients with AD
without CVD and AD with CVD.
Methods
Dementia diagnosis
Diagnoses of the following diseases were determined
during a meeting of two neurologists, a psychiatrist, and
a physician.
1) AD without CVD was diagnosed in patients who
met the NINCDS-ADRDA criteria for probable
AD [15] and had no CVD on MRI. On MRI, low
signal intensity on T1-weighted images, high signal
intensity on T2-weighted images, and high signal
intensity surrounding the low signal intensity areas
on FLAIR images were considered to indicate CVD.
2) AD with CVD was diagnosed according to the
NINCDS-ADRDA criteria for probable AD and on
evidence for the presence of CVD on MRI; however,
CVD lesions were judged to be concomitant with
AD and not responsible for cognitive deterioration.
Diagnoses of other dementing diseases were described
in the previous report [6].
Written informed consent was obtained from each
patient and from the family of those with dementia at entry
according to the Declaration of Helsinki (BMJ 1991; 302:
1194). The study was approved by the ethical committee of
Tohoku University Graduate School of Medicine, as well as
those of the Osaki-Tajiri SKIP Center.
Analyses
The main outcomes were QALY and lifetime expectancy
(i.e., the number of months between the onset of dementia
and death). The onset of dementia was confirmed by
extensive hearing of medical histories from their families.
Two-way ANOVA with the covariance of age and sex,
included the effects of NH replacement and DNP adminis-
tration for the AD and AD with CVD groups. Spearman’s
correlations were used to examine the relationship between
the DNP use periods and QALY as well as the lifetime
expectancy in both groups. Data were available for all 100
participants. The sample size was sufficiently powered to
analyze the group effect at a significance level of p < 0.05.
The error protection was = 0.05 and power was 0.8, thus
the effected size was 15 for each group.
Results
Demographics
As described previously, of the 100 patients with AD and
AD with CVD (both of which being diseases that can be
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not receive the drug due to treatment prior to the introduc-
tion of DNP in 1999 in Japan.Effects of NH replacement and DNP administration
Table 1 presents the effects of NH replacement and DNP
administration on lifetime expectancy and QALY. For the
pure AD group, there were positive SNH and DNP effects
on QALY as well as lifetime expectancy. As for the AD
with CVD group, there were no NH effects, only the DNP
effect on life expectancy with no effect on QALY.
On top of the previous analysis (DNP vs Non-DNP) [6],
AD with/without CVD were herein analyzed; thus the sig-
nificant p-values would be better less than 0.05/2 = 0.025.
The correlation between DNP and lifetime expectancy in
the AD without CVD group (F = 4.704) in Table 1 may be
influenced by the familywise error.Correlations between the periods of DNP use
Spearman’s correlation analyses revealed that all rela-
tionships between the period of DNP use and QALY, as
well as lifetime expectancy were significantly positive
(biologically meaningful) in the AD and AD with CVD
patients. Figure 1 presents the period of DNP use and
QALY for each AD group.Discussion
Summary of the results
Our previous study reported the positive effects of DNP
administration and NH replacement on lifetime expectancy
after the onset of AD; however, simple prolongation of
lifetime expectancy with possible decreased QOL remains a
problem. Instead, “healthy life expectancy,” i.e., QALY,
remains an important issue. Herein, we report the effects
on QALY. No covariance effects of age and sex may be due
to all patients were old and male to female ratio was not so
different between the groups.Table 1 Effects of NH replacement and DNP administration on lifeti
own homes NH replacement
no DNP DNP no DNP DN
AD n = 25 n = 27 n = 6 n =
lifetime expectancy 56.3 (44.6) 84.7 (36.3) 122.5 (59.7) 156
QALY 26.4 (17.8) 47.0 (20.5) 53.1 (18.2) 75.
AD with CVD n = 9 n = 14 n = 8 n =
lifetime expectancy 49.9 (41.6) 77.6 (32.9) 57.5 (44.6) 119
QALY 30.4 (21.3) 41.9 (16.1) 30.8 (27.1) 54.
Two-way ANOVAs with the covariance of age and gender were performed
*p < 0.05, **p < 0.01, ***p < 0.001
AD Alzheimer's disease, CVD cerebrovascular diseases, QALY quality-adusted life-yea
DNP donepezil, NH nursing homePositive correlation between DNP and/or NH replacement
and lifetime expectancy and QALY in pure AD
We previously discussed that while the possible correlation
between DNP and mortality remains uncertain, there is also
uncertainty regarding its effect on QALY. DNP may have a
negative effect on aspiration pneumonia due to the side
effect of nausea. An increased gastro-esophageal reflex
may also induce pneumonia. This suggests that the effect
of DNP on lifetime expectancy or QALY was not purely
pharmacological.
DNP administration can improve psychomotor speed
or attention function, associated with the frontal lobe
[16, 17]. It is consistent with the higher mortality in older
adults with lower perceptual speed [18]. Their activities of
daily living (ADL) are also stimulated. In a study of the
long-term effects of DNP and the use of community-based
home help service, the drug was reported to maintain
higher self-supported levels of instrumental ADL [19].
Rehabilitation also exhibits a long-term effect in decreasing
mortality, and particularly improves motor disability and
ADL [20], and prevents aspiration pneumonia [21].
Concomitant CVD negated the positive correlation with
QALY in AD with CVD, but the correlation between DNP
and lifetime expectancy remained
However, concomitant CVD negated such positive effects.
Each factor is discussed in turn.
The improvement of psychomotor speed or attention
function after DNP administration could be poorer in
the AD with CVD than in the pure AD patients. By
definition, no concomitant CVDs were located in the
“strategic” areas, such as the thalamus in the AD with
CVD patients; however, the effect of white matter
changes on the cholinergic network can be considered.
Indeed, the CHIPS scores in these patients were higher
than the pure AD patients (data not shown). Thus the
effect of DNP on psychomotor speed or attention function
is not “full-blown,” and the possible lack of a “synergistic”
effect with psychosocial intervention performed in the
NH cannot lead to any improvement of QALY.me expectancy and QALY
F-values covariance
P NH DNP interact age sex
7
.4 (37.8) 20.442*** 4.704* 0.002 0.873 2.482
7 (18.5) 15.123*** 11.859*** 0.000 0.854 3.738
4
.0 (46.2) 2.207 7.861** 1.034 0.265 0.364
4 (29.4) 0.74 3.608 0.65 0.077 2.162
r
Fig. 1 Period of DNP use and QALY for each AD group
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respect to lifetime expectancy. There were no remarkable
differences in the incidence of pneumonia and/or respira-
tory failure as the cause of death between the AD and AD
with CVD groups, and it is only possible to speculate the
reason for the effect of DNP on lifetime expectancy in the
absence of an effect on QALY. Taking into consideration
nausea as a side effect of DNP, together with increased
gastro-esophageal reflux, both may induce pneumonia; the
effect of DNP on lifetime expectancy was not considered as
being purely pharmacological. However, increasing the
level of acetylcholine to approach a healthy level in the
brain might influence the “energy level” of whole body
and thus the biological lifetime would be prolonged.
Another possibility is that when the QALY is evaluated
based on the HSUV, which is mainly based on ADLs,
meaningful but statistically small changes of QALY might
be underestimated.
Socio-economic effects
We calculated QALY of AD and AD with CVD, based
on the HSUV for AD by taking ADL into consideration.
There were no previous reports that estimated the
HSUVs according to the AD severity with ADL extent,Fig. 2 The models of the relationship between Alzheimer’s disease, cerebro
United States and Japanor considered complications, including CVD, but only
domestic studies on items of AD [22], long-term care [23],
and the extent of ADL [24] were found but there were no
reports that evaluated each of these issues together. We
estimated the HSUV value based on the ADL. We suggest
that the analysis of healthcare economics of dementia in
Japan could be improved through consideration of the
extent of ADL, in addition to the severity of AD.
Figure 2 presents our hypothesis of the concept of the
dementia state. In Western countries, few mild AD
patients also exhibit CVD and low levels of physical
ADL. However, in Japan, most mild AD patients could
exhibit CVD and low levels of physical ADL. This state
is called ‘boke' in Japanese.
The “Orange Plan”, a 5-year plan for the promotion of
measures against dementia in Japan, suggests that people
with dementia want to live in their own home as long as
possible. However, people with dementia or mild cognitive
impairment (MCI) face difficulties in maintaining their
daily lives. Maintaining a good level of drug compliance
remains an essential part in preserving their lives at home.
Also, the findings suggest that QALY in dementia is
affected by CVD; thus, indicating the importance of CVD
prevention. Indeed, the most common dementing diseasevascular disease, and low level of physical ADL in Europe and the
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stroke and dementia prevention (primary, secondary, and
tertiary) in the community are necessary to maintain the
QOL in older adults [25, 26].
Conclusions
Although this report has the limitation as all retrospective
analyses: i.e., the lack of randomization, we found a positive
correlation between DNP administration as well as NH
replacement and lifetime expectancy and QALY after the
onset of AD. However, concomitant CVD negated such
positive correlation with QALY. The findings suggest that
QALY in AD is affected by CVD, thus indicating the
importance of CVD prevention.
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